Patients entering the open-label dose optimization phase initiated treatment with MPH-LA 20 mg/day ; up/down titrated to their optimal dose ( at which there was balance between control of symptoms and side effects ) of 40 , 60 , or 80 mg/day in increments of 20 mg/week by week 12 or 13 .